Stinchcombe TE, et al. - The outcomes of limited-stage small cell lung cancer (LS-SCLC) patients 70 years old or older (elderly patients) were compared with those of younger than 70 years (younger patients) via analyzing individual patient data collected from 11 phase 2 or 3 trials for LS-SCLC conducted by the National Clinical Trials Network and activated from 1990 to 2010. For LS-SCLC, the standard treatment is comprised of platinum and etoposide with thoracic radiation followed by prophylactic cranial irradiation. Outcomes revealed that elderly patients with LS-SCLC had worse progression-free survival and overall survival, in addition to having more difficulty in tolerating therapy.